AstraZeneca likely to run new global trial on Covid-19 vaccine

LONDON (Reuters): AstraZeneca is likely to run an additional global trial to assess the efficacy of its Covid-19 vaccine, its chief executive Pascal Soriot was quoted as saying on Thursday (Nov 26) after questions over the results from its late-stage study.

Instead of adding the trial arm to an ongoing US process, a new study would be run to evaluate a lower dosage that performed better than a full amount in AstraZeneca’s studies, Soriot was quoted as saying in a Bloomberg News report.